RYALTRIS Nasal spray, suspension Ref.[50680] Active ingredients: Mometasone Olopatadine

Source: Health Products Regulatory Authority (IE)  Revision Year: 2021  Publisher: Glenmark Pharmaceuticals s.r.o, Hvezdova 1716/2b, Prague 4, 140 78, Czech Republic

Product name and form

Ryaltris 25 micrograms/actuation+600 micrograms/actuation nasal spray, suspension.

Pharmaceutical Form

Nasal Spray, Suspension.

White, homogeneous suspension.

Qualitative and quantitative composition

One delivered dose (the dose that leaves the actuator) contains mometasone furoate monohydrate equivalent to 25 microgram mometasone furoate and olopatadine hydrochloride equivalent to 600 micrograms olopatadine.

Excipient with known effect: Each actuation contains 0.02 mg benzalkonium chloride.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Mometasone

Mometasone is a topical glucocorticoid with local anti-inflammatory properties. It is likely that much of the mechanism for the effects of mometasone lies in its ability to inhibit the release of mediators of the inflammatory cascade.

Olopatadine

Olopatadine is a potent selective antiallergic/antihistaminic agent that exerts its effects through multiple distinct mechanisms of action.

List of Excipients

Microcrystalline cellulose (E460)
Dibasic sodium phosphate heptahydrate (E 339)
Carmellose sodium (E 466)
Sodium chloride
Benzalkonium chloride
Disodium edetate
Polysorbate 80 (E 433)
Hydrochloric acid (E 507)
Sodium hydroxide (E 524)
Water for injections

Pack sizes and marketing

The nasal spray is contained in a white, high density polyethylene bottle supplied with a metered-dose, manual polypropylene spray pump actuator. The actuator is fitted with a HDPE purple cap.

Pack sizes:

1 bottle of 20 ml with 9 g suspension (56 actuations),
1 bottle of 20 ml with 18 g suspension (120 actuations)
1 bottle of 30 ml with 29 g suspension (240 actuations).

Not all pack sizes may be marketed.

Marketing authorization holder

Glenmark Pharmaceuticals s.r.o, Hvezdova 1716/2b, Prague 4, 140 78, Czech Republic

Marketing authorization dates and numbers

PA1543/002/001

Date of first authorisation: 16th July 2021

Drugs

Drug Countries
RYALTRIS Ecuador, Ireland, Israel, Poland, Romania, United Kingdom

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.